<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6749704\results\search\disease\results.xml">
  <result pre="doi: 10.1186/s12916-019-1411-9 : Research Article The case for a universal" exact="hepatitis" post="C vaccine to achieve hepatitis C elimination ScottNicknick.scott@burnet.edu.au12WilsonDavid P.david.wilson@burnet.edu.au12ThompsonAlexander"/>
  <result pre="The case for a universal hepatitis C vaccine to achieve" exact="hepatitis" post="C elimination ScottNicknick.scott@burnet.edu.au12WilsonDavid P.david.wilson@burnet.edu.au12ThompsonAlexander J.alexander.thompson@svhm.org.au34BarnesEleanorellie.barnes@ndm.ox.ac.uk56El-SayedManalmanalhelsayed@yahoo.co.uk7BenzakenAdele Schwartzadelebenz@gmail.com8DrummerHeidi E.heidi.drummer@burnet.edu.au1910HellardMargaret E.margaret.hellard@burnet.edu.au121011[1], 0000"/>
  <result pre="The introduction of highly effective direct-acting antiviral (DAA) therapy for" exact="hepatitis" post="C has led to calls to eliminate it as"/>
  <result pre="suggest it is possible to develop a vaccine to prevent" exact="hepatitis" post="C. Using a mathematical model, we examined the potential"/>
  <result pre="a mathematical model, we examined the potential impact of a" exact="hepatitis" post="C vaccine on the feasibility and cost of achieving"/>
  <result pre="countries (47%). Conclusions These findings strongly support the case for" exact="hepatitis" post="C vaccine development as an urgent public health need,"/>
  <result pre="vaccine development as an urgent public health need, to ensure" exact="hepatitis" post="C elimination is achievable and at substantially reduced costs"/>
  <result pre="There are vast differences in the epidemiology and burden of" exact="hepatitis" post="C across the globe that have significant implications for"/>
  <result pre="significant implications for meeting the World Health Organization (WHO) 2030" exact="hepatitis" post="C elimination targets. A consequence is that responses to"/>
  <result pre="hepatitis C elimination targets. A consequence is that responses to" exact="hepatitis" post="C must be tailored to particular settings; major considerations"/>
  <result pre="and human resources). The majority of high-income countries have concentrated" exact="hepatitis" post="C epidemics with transmission predominantly occurring among PWID [1–3]."/>
  <result pre="occurring among PWID [1–3]. In settings where the prevalence of" exact="hepatitis" post="C among PWID is less than approximately 50%, mathematical"/>
  <result pre="number of European countries [5–8]. However, if the prevalence of" exact="hepatitis" post="C among PWID is extremely high (greater than approximately"/>
  <result pre="therefore likely to need significant additional prevention measures to achieve" exact="hepatitis" post="C elimination. Many low- and middle-income countries have generalised"/>
  <result pre="in addition to transmission among PWID. The prospects of reducing" exact="hepatitis" post="C incidence through treatment-as-prevention in these countries is low"/>
  <result pre="sources of transmission, and minimal existing prevention interventions. Vaccines for" exact="hepatitis" post="C have been in pre-clinical development since the discovery"/>
  <result pre="C have been in pre-clinical development since the discovery of" exact="hepatitis" post="C virus almost 30 years ago. Two candidates have reached"/>
  <result pre="the possibility of developing a vaccine for the prevention of" exact="hepatitis" post="C within the next 5–10 years. However, vigorous research and"/>
  <result pre="within the next 5–10 years. However, vigorous research and development of" exact="hepatitis" post="C vaccine candidates and the immunological requirements for natural"/>
  <result pre="of direct acting antiviral therapies (DAAs), highly effective treatments for" exact="hepatitis" post="C. The global spotlight is currently focussed on the"/>
  <result pre="imagine a vaccine not playing a central role in long-term" exact="hepatitis" post="C control strategies for the majority of the world."/>
  <result pre="In this study, we used a mathematical model to project" exact="hepatitis" post="C incidence reduction following the implementation of a variety"/>
  <result pre="achieve the WHO elimination target of an 80% reduction in" exact="hepatitis" post="C incidence by 2030 in the most cost-effective way"/>
  <result pre="The analysis was performed with and without a theoretical prophylactic" exact="hepatitis" post="C vaccine, to determine if additional impact and/or cost"/>
  <result pre="and relative importance that a future vaccine has in achieving" exact="hepatitis" post="C elimination. Methods Model description We used a dynamic"/>
  <result pre="Methods Model description We used a dynamic compartmental model of" exact="hepatitis" post="C transmission (Fig. 1). The model included two population"/>
  <result pre="15–64-year-old population, as a proxy for non-PWID at risk of" exact="hepatitis" post="C infection in settings with generalised or mixed epidemics)."/>
  <result pre="rather than antibody testing due to known past exposure to" exact="hepatitis" post="C. Susceptible individuals could become infected according to the"/>
  <result pre="C. Susceptible individuals could become infected according to the current" exact="hepatitis" post="C prevalence within their population group, whether or not"/>
  <result pre="constant that allows the model to be adapted to the" exact="hepatitis" post="C prevalence in the given setting. For concentrated epidemic"/>
  <result pre="prevalence of injecting drug use [9] and the prevalence of" exact="hepatitis" post="C among PWID [9] and the general population [14,"/>
  <result pre="and the general community. Limited global datasets were available with" exact="hepatitis" post="C prevalence estimates, meaning that the models were calibrated"/>
  <result pre="be considered to be the theoretical maximum attainable impact of" exact="hepatitis" post="C elimination programmes. By assuming high coverage of testing"/>
  <result pre="theoretical settings that had concentrated epidemics (25%, 50% or 75%" exact="hepatitis" post="C prevalence among PWID), generalised epidemics (1%, 2%, 3%,"/>
  <result pre="epidemics (1%, 2%, 3%, 5%, 10%, 15%, 25% or 30%" exact="hepatitis" post="C prevalence among the general community) and mixed epidemics"/>
  <result pre="among the general community) and mixed epidemics (all combinations of" exact="hepatitis" post="C prevalence among PWID and the general community). Results"/>
  <result pre="period (2018–2030) This was implemented as 1/12th of people with" exact="hepatitis" post="C in the general population being diagnosed every year"/>
  <result pre="income classification AND the total number of people living with" exact="hepatitis" post="C was &amp;gt; 5 times the total number of estimated"/>
  <result pre="hepatitis C was &amp;gt; 5 times the total number of estimated" exact="hepatitis" post="C-infected PWID. This classification was used as without modelling"/>
  <result pre="unable to produce the correct number of people living with" exact="hepatitis" post="C based on injecting drug use-related transmission alone. Countries"/>
  <result pre="the national level), since their PWID populations had significantly higher" exact="hepatitis" post="C prevalence than the general community, and so the"/>
  <result pre="was taken for costs (Table 2). The commodity cost of" exact="hepatitis" post="C antibody tests, RNA tests, and treatment were based"/>
  <result pre="file 1: Appendix E—Table S7). The median relative reduction in" exact="hepatitis" post="C incidence in the optimal strategies without a vaccine"/>
  <result pre="impact of a vaccine on the feasibility and cost of" exact="hepatitis" post="C elimination. Total cases averted 2018–2030 using the optimal"/>
  <result pre="among PWID. Common to these countries is a very high" exact="hepatitis" post="C prevalence among PWID (&amp;gt; 80%). The extremely high prevalence"/>
  <result pre="meant that there were not many uninfected PWID, and so" exact="hepatitis" post="C incidence was low. Scaling up treatment led to"/>
  <result pre="vaccines can play an important role in the elimination of" exact="hepatitis" post="C. We found that for the majority of settings,"/>
  <result pre="of settings, the WHO target of an 80% reduction in" exact="hepatitis" post="C incidence by 2030 is unlikely to be achieved"/>
  <result pre="be achieved without additional prevention measures. Integrating a vaccine within" exact="hepatitis" post="C testing and treatment programmes could greatly improve the"/>
  <result pre="fewer than 29% of countries analysed were able to reduce" exact="hepatitis" post="C incidence by 80% by 2030 in the model"/>
  <result pre="treatment programmes have the potential to produce major gains towards" exact="hepatitis" post="C elimination, they have limitations that will require additional"/>
  <result pre="they have limitations that will require additional intervention, and a" exact="hepatitis" post="C vaccine is worth pursuing to fill this gap."/>
  <result pre="developed countries, a vaccine could significantly reduce the costs of" exact="hepatitis" post="C elimination. When a vaccine was modelled at US$200"/>
  <result pre="concentrated and mixed epidemic settings, respectively. Therefore, a vaccine for" exact="hepatitis" post="C must be cheap and simple to manufacture so"/>
  <result pre="for Disease Control in the USA prices adult vaccines for" exact="hepatitis" post="B at US$30.81; human papillomavirus at US$144.18; measles, mumps,"/>
  <result pre="B at US$30.81; human papillomavirus at US$144.18; measles, mumps, and" exact="rubella" post="at US$45.65; and varicella at US$77.57 [27]. However, in"/>
  <result pre="at US$77.57 [27]. However, in low- and middle-income countries, the" exact="hepatitis" post="B vaccine can cost as little as US$0.16 per"/>
  <result pre="additional prevention measures, the optimal global incidence reduction strategy for" exact="hepatitis" post="C is to implement targeted test and treat programmes"/>
  <result pre="test and treat programmes among those at high risk of" exact="hepatitis" post="C infection and to implement hepatitis C vaccination through"/>
  <result pre="at high risk of hepatitis C infection and to implement" exact="hepatitis" post="C vaccination through these programmes. It is estimated that"/>
  <result pre="programmes. It is estimated that only 20% of people with" exact="hepatitis" post="C were diagnosed globally in 2015 [22], meaning that"/>
  <result pre="It is therefore worth examining the potential to combine a" exact="hepatitis" post="C vaccine with other vaccines targeting this age group"/>
  <result pre="vaccines targeting this age group such as human papillomavirus or" exact="hepatitis" post="B. Harm reduction for PWID has an important role"/>
  <result pre="for PWID has an important role to play in the" exact="hepatitis" post="C elimination agenda. In sensitivity analyses, we tested the"/>
  <result pre="and opioid substitution therapy should be considered essential components of" exact="viral hepatitis" post="strategies as recommended by the WHO [29]. The total"/>
  <result pre="opioid substitution therapy should be considered essential components of viral" exact="hepatitis" post="strategies as recommended by the WHO [29]. The total"/>
  <result pre="the WHO [29]. The total cost of reaching the WHO" exact="hepatitis" post="C elimination targets has been estimated at US$51 billion"/>
  <result pre="globally [30]. For many countries, the direct costs associated with" exact="hepatitis" post="C are currently low, because there are no or"/>
  <result pre="because there are no or limited services available to manage" exact="hepatitis" post="C-related liver disease. As a result, the required outlay"/>
  <result pre="are no or limited services available to manage hepatitis C-related" exact="liver disease." post="As a result, the required outlay on hepatitis C"/>
  <result pre="C-related liver disease. As a result, the required outlay on" exact="hepatitis" post="C testing and treatment programmes represents new costs with"/>
  <result pre="direct economic benefits. However, when the indirect economic benefits of" exact="hepatitis" post="C elimination are considered, such as a larger and"/>
  <result pre="other programmes as a way to improve prevention and reduce" exact="hepatitis" post="C transmission—only one component of hepatitis C elimination—and the"/>
  <result pre="improve prevention and reduce hepatitis C transmission—only one component of" exact="hepatitis" post="C elimination—and the vaccine was modelled to be delivered"/>
  <result pre="treatment programmes because they will also be required to reduce" exact="hepatitis" post="C morbidity and mortality. Our estimate that a US$200"/>
  <result pre="in the estimated total cost, should financing be obtained for" exact="hepatitis" post="C elimination. The total cost of developing a vaccine"/>
  <result pre="of the first phase II efficacy trial of a prophylactic" exact="hepatitis" post="C vaccine designed to generate cellular immunity, released in"/>
  <result pre="this study, it is a reminder that a vaccine for" exact="hepatitis" post="C will still require significant research and development investment."/>
  <result pre="with 28 past and current phase II trials [32]. For" exact="hepatitis" post="C, the market size of a vaccine will be"/>
  <result pre="DAAs to underpin global elimination efforts is blocking interest in" exact="hepatitis" post="C vaccine development. Like almost all vaccines, a public-private"/>
  <result pre="this study relate to the hypothetical vaccine. Prophylactic vaccines for" exact="hepatitis" post="C are currently undergoing clinical trials, and their final"/>
  <result pre="restored after attaining DAA-mediated viral clearance and is responsive to" exact="hepatitis" post="C vaccination. However, our sensitivity analysis suggests that vaccine"/>
  <result pre="costs could be avoided by inclusion with human papillomavirus or" exact="hepatitis" post="B vaccine schedules. When a vaccine is available, it"/>
  <result pre="this study was to generate evidence that a vaccine for" exact="hepatitis" post="C has the potential to unlock health and economic"/>
  <result pre="stabilised treatment. Conclusion These findings strongly support the case for" exact="hepatitis" post="C vaccine development as an urgent public health need,"/>
  <result pre="vaccine development as an urgent public health need, to ensure" exact="hepatitis" post="C elimination is achievable and at substantially reduced costs"/>
  <result pre="Appendix A. country specific data inputs (population sizes, prevalence of" exact="hepatitis" post="C among PWID and the general community, and staff"/>
  <result pre="settings (results from concentrated, generalised and mixed epidemic settings, with" exact="hepatitis" post="C prevalence of 25/50/75% among PWID +/− 1/2/3/5/10/15/20/25/30% among the"/>
  <result pre="funding to her institution from GSK to deliver studies in" exact="hepatitis" post="C vaccines that encode class II invariant chain. MH"/>
  <result pre="Gilead Sciences, AbbVie, and BMS. References References 1.ShepardCWFinelliLAlterMJGlobal epidemiology of" exact="hepatitis" post="C virus infectionLancet Infect Dis20055955856710.1016/S1473-3099(05)70216-416122679 2.HajarizadehBGrebelyJDoreGJEpidemiology and natural history"/>
  <result pre="of HCV infectionNat Rev Gastroenterol Hepatol201310955356210.1038/nrgastro.2013.10723817321 3.NelsonPKMathersBMCowieBHaganHDes JarlaisDHoryniakDDegenhardtLGlobal epidemiology of" exact="hepatitis" post="B and hepatitis C in people who inject drugs:"/>
  <result pre="Rev Gastroenterol Hepatol201310955356210.1038/nrgastro.2013.10723817321 3.NelsonPKMathersBMCowieBHaganHDes JarlaisDHoryniakDDegenhardtLGlobal epidemiology of hepatitis B and" exact="hepatitis" post="C in people who inject drugs: results of systematic"/>
  <result pre="in people who inject drugs: results of systematic reviewsLancet2011378979157158310.1016/S0140-6736(11)61097-021802134 4.ScottNSacks-DavisRPedranaADoyleJThompsonAHellardMEliminating" exact="hepatitis" post="C: the importance of frequent testing of people who"/>
  <result pre="HCV incidence and mortality elimination targets: a cost-effectiveness modelGut20176681507151510.1136/gutjnl-2016-31150427196586 6.ScottNDoyleJWilsonDPWadeAHowellJPedranaAThompsonAHellardMReaching" exact="hepatitis" post="C virus elimination targets requires health system interventions to"/>
  <result pre="who inject drugs in EuropeJ Hepatol20186840241110.1016/j.jhep.2017.10.01029080808 8.ScottNÓlafssonSGottfreðssonMTyrfingssonTRúnarsdóttirVHansdottirIHernandezUBSigmundsdóttirGHellardMModelling the elimination of" exact="hepatitis" post="C as a public health threat in Iceland: a"/>
  <result pre="2019. Accessed 13 June 2019 12.MicallefJMKaldorJMDoreGJSpontaneous viral clearance following acute" exact="hepatitis" post="C infection: a systematic review of longitudinal studiesJ Viral"/>
  <result pre="Accessed 1 May 2018 14.BlachSZeuzemSMannsMAltraifIDubergA-SMuljonoDHWakedIAlavianSMLeeM-HNegroFGlobal prevalence and genotype distribution of" exact="hepatitis" post="C virus infection in 2015: a modelling studyLancet Gastroenterol"/>
  <result pre="studyLancet Gastroenterol Hepatol20172316117610.1016/S2468-1253(16)30181-928404132 15.GowerEEstesCBlachSRazavi-ShearerKRazaviHGlobal epidemiology and genotype distribution of the" exact="hepatitis" post="C virus infectionJ Hepatol2014611 SupplS45S5710.1016/j.jhep.2014.07.02725086286 16.collab: World Health OrganizationDisability"/>
  <result pre="syringe provision and opiate substitution therapy on the incidence of" exact="hepatitis" post="C virus in injecting drug users: pooling of UK"/>
  <result pre="ribavirin in treatment-naive and previously treated patients with genotype 1" exact="hepatitis" post="C virus infection (LONESTAR): an open-label, randomised, phase 2"/>
  <result pre="eraPLoS One2018138e020210910.1371/journal.pone.020210930114207 29.collab: World Health OrganizationGlobal health sector strategy on" exact="viral hepatitis" post="2016–20212016 30.Pedrana A, Howell J, Schröder S, Scott N,"/>
  <result pre="One2018138e020210910.1371/journal.pone.020210930114207 29.collab: World Health OrganizationGlobal health sector strategy on viral" exact="hepatitis" post="2016–20212016 30.Pedrana A, Howell J, Schröder S, Scott N,"/>
 </snippets>
</snippetsTree>
